AIM: To examine whether administration of lentinan, purified β-1, 3-glucan, can prolong survival in advanced gastric cancer patients receiving S-1-based chemotherapy. METHODS: Since 2004, 78 patients with metastatic or recurrent gastric cancer have received S-1-based chemotherapy as first-line treatment. Survival, side effects, and the ratio of granulocytes/lymphocytes (G/L ratio) were compared between 2 groups of patients who received chemo-immunotherapy using lentinan and chemotherapy alone. RESULTS: Median overall survival was significantly longer in the former group than in the latter group [689 d (95% CI: 431-2339 d) vs 565 d (95% CI: 323-662 d), P = 0.0406]. In addition, the G/L ratio in patients who received lentinan was maintained around or below 2, which was significantly lower than that in patients who received chemotherapy alone (P < 0.001). CONCLUSION: Chemo-immunotherapy with lentinan offers a significant advantage over S-1-based chemotherapy alone in terms of survival in patients with advanced gastric cancer.
AIM: To examine whether administration of lentinan, purified β-1, 3-glucan, can prolong survival in advanced gastric cancerpatients receiving S-1-based chemotherapy. METHODS: Since 2004, 78 patients with metastatic or recurrent gastric cancer have received S-1-based chemotherapy as first-line treatment. Survival, side effects, and the ratio of granulocytes/lymphocytes (G/L ratio) were compared between 2 groups of patients who received chemo-immunotherapy using lentinan and chemotherapy alone. RESULTS: Median overall survival was significantly longer in the former group than in the latter group [689 d (95% CI: 431-2339 d) vs 565 d (95% CI: 323-662 d), P = 0.0406]. In addition, the G/L ratio in patients who received lentinan was maintained around or below 2, which was significantly lower than that in patients who received chemotherapy alone (P < 0.001). CONCLUSION: Chemo-immunotherapy with lentinan offers a significant advantage over S-1-based chemotherapy alone in terms of survival in patients with advanced gastric cancer.
Authors: H Iwase; M Shimada; T Tsuzuki; K Ina; M Sugihara; J Haruta; M Shinoda; T Kumada; H Goto Journal: Oncology Date: 2011-06-10 Impact factor: 2.935
Authors: A Ohtsu; N Boku; F Tamura; K Muro; Y Shimada; K Saigenji; S Akazawa; M Kitajima; R Kanamaru; T Taguchi Journal: Am J Clin Oncol Date: 1998-08 Impact factor: 2.339
Authors: K Yamaguchi; T Shimamura; I Hyodo; W Koizumi; T Doi; H Narahara; Y Komatsu; T Kato; S Saitoh; T Akiya; M Munakata; Y Miyata; Y Maeda; H Takiuchi; S Nakano; T Esaki; F Kinjo; Y Sakata Journal: Br J Cancer Date: 2006-06-19 Impact factor: 7.640
Authors: A Sulkes; J Smyth; C Sessa; L Y Dirix; J B Vermorken; S Kaye; J Wanders; H Franklin; N LeBail; J Verweij Journal: Br J Cancer Date: 1994-08 Impact factor: 7.640
Authors: Claire Barton; Kim Vigor; Robert Scott; Paul Jones; Heike Lentfer; Heather J Bax; Debra H Josephs; Sophia N Karagiannis; James F Spicer Journal: Cancer Immunol Immunother Date: 2016-07-29 Impact factor: 6.968